Ergomed (LON:ERGO)‘s stock had its “buy” rating restated by research analysts at Numis Securities in a research report issued on Thursday, Digital Look reports. They presently have a GBX 267 ($3.49) price target on the stock, up from their prior price target of GBX 190 ($2.48). Numis Securities’ price target would indicate a potential upside of 14.59% from the company’s current price.
Ergomed stock traded up GBX 29 ($0.38) during midday trading on Thursday, reaching GBX 233 ($3.04). The stock had a trading volume of 122,695 shares, compared to its average volume of 28,490. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.48 and a quick ratio of 1.48. Ergomed has a 52-week low of GBX 145 ($1.89) and a 52-week high of GBX 248 ($3.24). The firm has a market capitalization of $107.93 million and a P/E ratio of -11.65.
In related news, insider Jan Petracek bought 79,405 shares of the company’s stock in a transaction on Tuesday, April 16th. The shares were acquired at an average cost of GBX 153 ($2.00) per share, for a total transaction of £121,489.65 ($158,747.75).
Ergomed plc provides clinical research, and drug development and safety and medical information services in the United Kingdom and internationally. The company offers clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies.
Receive News & Ratings for Ergomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed and related companies with MarketBeat.com's FREE daily email newsletter.